Pre-made Brodalumab benchmark antibody ( Whole mAb, anti-IL17RA/IL17R therapeutic antibody, Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-082-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody
INN Name	Brodalumab
Target	IL17R
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2011
Year Recommended	2012
Companies	Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma
Conditions Approved	Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis
Conditions Active	Axial Spondylarthritis;Systemic scleroderma;Palmoplantar pustulosis
Conditions Discontinued	Asthma;Crohn's disease;Rheumatoid arthritis
Development Tech	Abgenix XenoMouse